Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney diseaseGlobeNewsWire • 11/22/21
Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Galapagos reports commercial and operational progress at Q3 financial resultsGlobeNewsWire • 11/04/21
Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding PatientsBenzinga • 10/05/21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congressGlobeNewsWire • 10/04/21
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's DiseaseBenzinga • 10/04/21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's DiseaseGlobeNewsWire • 10/04/21
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISGlobeNewsWire • 09/17/21
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/07/21
Galapagos reports H1 financial results with refocused pipeline and operational progressGlobeNewsWire • 08/05/21
Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage StudyBenzinga • 07/15/21
Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis PatientsBenzinga • 07/15/21
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis studyGlobeNewsWire • 07/14/21